News >

FDA Approves Frontline Fulvestrant for HR-Positive/HER2-Negative Breast Cancer

Jason M. Broderick @jasoncology
Published: Monday, Aug 28, 2017

Matthew J.C. Ellis, MB BChir, PhD

Matthew Ellis, MD, PhD
The FDA has approved fulvestrant (Faslodex) for use in hormone receptor (HR)-positive, HER2-negative locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.

In February 2016, the FDA approved fulvestrant in combination with palbociclib (Ibrance) for women with HR-positive, HER2-negative advanced or metastatic breast cancer, whose cancer has progressed after endocrine therapy.
Ellis MJ, Bondarenko I, Trishkina E, et al. FALCON: a phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer. Presented at: 2016 ESMO Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract LBA14.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication